Related Experiment Video
Updated: Apr 17, 2026
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma
Lilia Dimitrov1, Christopher S Hong2, Chunzhang Yang2
11. Barts and the London School of Medicine and Dentistry, Greater London, E1 2AD, United Kingdom ; 2. Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA.
Abstract:
In the last five years, IDH1 mutations in human malignancies have significantly shaped the diagnosis and management of cancer patients. Ongoing intense research efforts continue to alter our understanding of the role of the IDH1 mutation in tumor formation. Currently, evidence suggests the IDH1 mutation to be an early event in tumorigenesis with multiple downstream oncogenic consequences including maintenance of a hypermethylator phenotype, alterations in HIF signalling, and disruption of collagen maturation contributing to a cancer-promoting extracellular matrix. The most recent reports elucidating these mechanisms is described in this review with an emphasis on the pathogenesis of the IDH1 mutation in glioma. Conflicting findings from various studies are discussed, in order to highlight areas warranting further research. Finally, the latest progress in developing novel therapies against the IDH1 mutation is presented, including recent findings from ongoing phase 1 clinical trials and the exciting prospect of vaccine immunotherapy targeting the IDH1 mutant protein.
Insights
IDH1 mutations are early cancer events driving tumor growth through epigenetic and signaling changes. New therapies, including immunotherapies, show promise for treating IDH1-mutated cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Isocitrate dehydrogenase 1 (IDH1) mutations are increasingly recognized as significant drivers in various human malignancies.
- These mutations play a critical role in early tumorigenesis and cancer progression.
Purpose of the Study:
- This review elucidates the pathogenic mechanisms of IDH1 mutations.
- It emphasizes the role of IDH1 mutations in glioma pathogenesis.
- The review also highlights recent therapeutic advancements.
Main Methods:
- Review of current scientific literature and clinical trial data.
- Analysis of molecular mechanisms including hypermethylation, HIF signaling, and extracellular matrix disruption.
- Discussion of ongoing clinical trials for IDH1-targeted therapies.
Main Results:
- IDH1 mutations contribute to a hypermethylator phenotype and alter hypoxia-inducible factor (HIF) signaling.
- Disruption of collagen maturation by IDH1 mutations promotes a pro-tumorigenic extracellular matrix.
- Early-phase clinical trials show promise for novel therapies, including IDH1-targeted vaccines.
Conclusions:
- IDH1 mutations are early oncogenic events with diverse downstream consequences.
- Understanding these mechanisms is crucial for developing effective cancer treatments.
- Targeted therapies and immunotherapies represent promising avenues for IDH1-mutated cancers.
